Nassiri Nader, Farahangiz Saman, Rahnavardi Mohammad, Rahmani Laleh, Nassiri Nariman
Department of Ophthalmology, Imam Hossein Medical Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
J Cataract Refract Surg. 2008 Jun;34(6):902-8. doi: 10.1016/j.jcrs.2008.03.007.
To evaluate the effect of intraoperative use of mitomycin-C (MMC) on the corneal endothelium during excimer laser photorefractive keratectomy (PRK).
Vanak Eye Surgery Center, Tehran, Iran.
This nonrandomized trial comprised 81 patients (162 eyes) with bilateral low to moderate myopia and adequate corneal thickness to allow PRK (estimated postoperative residual stromal thickness >350 microm without considering epithelial thickness). The indication for intraoperative application of MMC 0.02% (0.2 mg/mL) was an ablation depth of 75 microm or more. Patients were divided into 3 groups: bilateral (both eyes treated with MMC), unilateral (only 1 eye treated with MMC), and untreated (no eye treated with MMC). Visual acuity, refraction, endothelial cell density (ECD), and corneal thickness were measured preoperatively as well as 1 week and 1, 3, and 6 months postoperatively.
Overall, 76 eyes were treated with MMC. Eyes treated with MMC and untreated eyes were comparable in postoperative visual acuity and refraction. Preoperative to postoperative changes in ECD were statistically significantly greater in the treated eyes (-14.8%) than in untreated eyes (-5.1%) 6 months after PRK (P<.001). Longer MMC contact time (P<.001) and male sex (P= .04) were the only factors independently associated with greater endothelial cell loss.
The prophylactic use of diluted intraoperative MMC 0.02% solution caused corneal endothelial cell loss. The rate of cell loss was correlated with the duration of MMC exposure.
评估准分子激光屈光性角膜切削术(PRK)术中使用丝裂霉素-C(MMC)对角膜内皮的影响。
伊朗德黑兰瓦纳克眼科手术中心。
这项非随机试验纳入了81例(162只眼)双侧轻至中度近视且角膜厚度足够进行PRK的患者(估计术后残余基质厚度>350微米,不考虑上皮厚度)。术中应用0.02%(0.2毫克/毫升)MMC的指征是消融深度达75微米或更深。患者分为3组:双侧(双眼均用MMC治疗)、单侧(仅1眼用MMC治疗)和未治疗组(无眼用MMC治疗)。术前以及术后1周、1、3和6个月测量视力、屈光、内皮细胞密度(ECD)和角膜厚度。
总体而言,76只眼接受了MMC治疗。接受MMC治疗的眼和未治疗的眼在术后视力和屈光方面具有可比性。PRK术后6个月,治疗眼的ECD术前至术后变化(-14.8%)在统计学上显著大于未治疗眼(-5.1%)(P<0.001)。MMC接触时间更长(P<0.001)和男性(P = 0.04)是与更大内皮细胞丢失独立相关的唯一因素。
术中预防性使用稀释的0.02%MMC溶液会导致角膜内皮细胞丢失。细胞丢失率与MMC暴露持续时间相关。